약물명 | 회사명 | 치료 영역 | 년도 |
Nivolumab (Opdivo) | Bristol-Myers Squibb Co. | Oncology | 2015 |
Palbociclib (Ibrance) | Pfizer Inc. | Oncology | 2015 |
Sacubitril plus valsartan (LCZ-696) | Novartis International AG | 심혈관 질환 | 2015 |
Secukinumab (Cosentyx) | Novartis International AG | 과도한 면역반응/자가면역 | 2015 |
Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak) | AbbVie Inc. | 호흡기 질병 | 2015 |
Idelalisib (Zydelig) | Gilead Sciences Inc. | Oncology | 2014 |
Sofosbuvir (Sovaldi) | Gilead Sciences Inc. | 전염병 | 2014 |
Vilanterol plus umeclidinium (Anoro Ellipta) | GlaxoSmithKline plc, Theravance Biopharma Inc. | 호흡기 질병 | 2014 |
Apremilast (Otezla) | Celgene Corporation | 과도한 면역반응/자가면역 | 2013 |
Fluticasone furoate plus vilanterol trifenatate (Relovair) | GlaxoSmithKline plc, Theravance Biopharma Inc. | 호흡기 질병 | 2013 |
Icosapent ethyl ester (Vascepa) | Amarin Corporation plc | 심혈관 질환 | 2013 |
Pomalidomide (Pomalyst) | Celgene Corporation | Oncology | 2013 |
Trastuzumab emtansine (T-DM1) | Roche | Oncology | 2013 |
Umeclidinium plus vilanterol (Zephyr) | GlaxoSmithKline plc, Theravance Biopharma Inc. | 호흡기 질병 | 2013 |